Rep. Gilbert Cisneros Buys Vaxcyte (PCVX) Stock
U.S. House member Gilbert Cisneros bought shares of Vaxcyte, Inc. as part of his investment strategy.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros bought between $1,001 and $15,000 of Vaxcyte, Inc. ($PCVX) stock on May 13, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $PCVX is down 13.1% after 1 week, down 12.5% after 1 month and up 17.3% to date (from the $54.25 close on May 13, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Vaxcyte, Inc. ($PCVX) | Buy | May 13, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
PCVX
Vaxcyte, Inc.
Key Points
- Gilbert Cisneros bought Vaxcyte, Inc. shares valued between $1,001 and $15,000 on May 13, 2026, with the stock priced at $49.31 at the time.
- Vaxcyte's stock is currently trading well below its 52-week high of $65.00, indicating potential for growth as analysts have a positive outlook.
- Analysts have set a mean price target of $109.00 for Vaxcyte, reflecting strong buy ratings from multiple firms.
Get $PCVX trade alerts by text
We text you when insiders, Congress or big funds trade $PCVX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Vaxcyte, Inc. alert may contain errors. Disclosures
Gilbert Cisneros Makes a Purchase
On May 13, 2026, U.S. House member Gilbert Cisneros bought shares of Vaxcyte, Inc. (NasdaqGS: PCVX) valued between $1,001 and $15,000. The stock was trading at $49.31 on that day. This purchase was reported on June 9, 2026.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Why Cisneros' Purchase Matters
Cisneros' investment comes at a time when Vaxcyte's shares are trading significantly below their 52-week high of $65.00. This could indicate a strategic move to capitalize on potential growth in the healthcare sector, particularly in biotechnology, where Vaxcyte operates.
Institutional Activity
No other funds reported changes in their positions with Vaxcyte, so there are no additional institutional insights to share at this time.
How Vaxcyte, Inc. Stock Has Traded
Vaxcyte's stock is currently priced at $49.31, which is below its 50-day moving average of $58.43. This suggests that the stock may be undervalued compared to its recent performance. The stock has fluctuated between $31.89 and $65.00 over the past year, providing a wide range for potential investors to consider.
Recent Earnings
Vaxcyte has not yet reported earnings for the quarter ending November 3, 2026. The company has faced challenges, as indicated by its negative earnings per share (EPS) of -$7.63. Investors will be looking for improvements in its financial performance in the upcoming earnings report.
Insider Buying and Selling at Vaxcyte, Inc.
Recently, several insiders at Vaxcyte have made notable transactions. On June 18, 2026, CEO Grant Pickering bought 225 shares at an average price of $1.79, totaling about $402.75. Meanwhile, President and CFO Andrew Guggenhime sold 10,000 shares for $530,000 under a planned sale, while also buying 10,000 shares at a price of $5.35, totaling $53,500. These transactions reflect a mix of confidence and strategic planning among the company's leadership.
Analysts Set New Price Targets
Analysts maintain a strong outlook on Vaxcyte, with firms such as Cantor Fitzgerald reiterating an Overweight rating and a price target of $120. Other firms, like BTIG and Needham, have also issued buy ratings with targets ranging from $89 to $122. This consensus reflects confidence in the company's future growth potential, especially considering the innovative vaccines it is developing.
What Vaxcyte, Inc. Does
Vaxcyte, Inc., based in San Carlos, California, focuses on developing vaccines to prevent bacterial infectious diseases. Its lead candidate, VAX-24, aims to protect infants from invasive pneumococcal disease. The company's innovative approach to vaccine development is critical in a time where infectious diseases remain a significant public health concern.
What's Ahead for Vaxcyte, Inc.
Investors will be watching Vaxcyte closely as it approaches its next earnings report on November 3, 2026. Gilbert Cisneros' recent purchase adds interest to the company, especially as it seeks to improve its financial standing. The recent 13F filings and insider activity provide insights into the company's current position, but potential investors should consider the risks and rewards involved.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $PCVX (May 13, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts